EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Phase 1 Terminated
6 enrolled 11 charts
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
Phase 2 Terminated
59 enrolled 8 charts
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 2 Terminated
11 enrolled 6 charts
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
Phase 1 Terminated
3 enrolled
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
Phase 3 Terminated
105 enrolled
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Phase 1/2 Terminated
23 enrolled 13 charts
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Phase 1/2 Terminated
23 enrolled 12 charts
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
Phase 2 Terminated
10 enrolled
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
Phase 1 Terminated
1 enrolled 7 charts
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2 Terminated
1 enrolled 4 charts
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
Phase 1/2 Terminated
1 enrolled 7 charts
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Phase 2 Terminated
15 enrolled 8 charts
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
Phase 2 Terminated
4 enrolled 11 charts
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Phase 2 Terminated
1 enrolled 5 charts
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 1/2 Terminated
1 enrolled 5 charts
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Phase 2 Terminated
6 enrolled 5 charts
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
Phase 2 Terminated
16 enrolled 6 charts
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Phase 2 Terminated
8 enrolled 11 charts
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia
Phase 3 Terminated
43 enrolled
Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer
Phase NA Terminated
8 enrolled
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
Phase 2 Terminated
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
Phase NA Terminated
4 enrolled
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
Phase 2 Terminated
42 enrolled 8 charts
Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Phase 3 Terminated
53 enrolled